Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
Add more filters










Database
Language
Publication year range
1.
Cureus ; 14(7): e27278, 2022 Jul.
Article in English | MEDLINE | ID: mdl-36039261

ABSTRACT

Humans maintain core body temperature via a complicated system of physiologic mechanisms that counteract heat/cold fluctuations from metabolism, exertion, and the environment. Overextension of these mechanisms or disruption of body temperature homeostasis leads to bodily dysfunction, culminating in a syndrome analogous to exertional heat stroke (EHS). The inability of this thermoregulatory process to maintain the body temperature is caused by either thermal stress or certain drugs. EHS is a syndrome characterized by hyperthermia and the activation of systemic inflammation. Several drug-induced hyperthermic syndromes may resemble EHS and share common mechanisms. The purpose of this article is to review the current literature and compare exertional heat stroke (EHS) to three of the most widely studied drug-induced hyperthermic syndromes: malignant hyperthermia (MH), neuroleptic malignant syndrome (NMS), and serotonin syndrome (SS). Drugs and drug classes that have been implicated in these conditions include amphetamines, diuretics, cocaine, antipsychotics, metoclopramide, selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants (TCAs), and many more. Observations suggest that severe or fulminant cases of drug-induced hyperthermia may evolve into an inflammatory syndrome best described as heat stroke. Their underlying mechanisms, symptoms, and treatment approaches will be reviewed to assist in accurate diagnosis, which will impact the management of potentially life-threatening complications.

2.
Cureus ; 13(9): e17929, 2021 Sep.
Article in English | MEDLINE | ID: mdl-34660121

ABSTRACT

The cost of health care has been rising in the United States and globally and will continue to increase. Intensive care unit (ICU) care carries a significant portion of the cost for the hospitals. The Institute of Medicine and subsequent studies have suggested that medication errors account for significant morbidity, mortality, and cost, frequently encountered in the ICU. Over the past three decades, clinical pharmacists have emerged from dispensing medication to getting involved in direct patient care and have become an integral part of the multidisciplinary critical care team. Clinical pharmacists play a significant role in reducing medication errors and costs, medication reconciliation, antibiotic stewardship, and patient and health care provider education. This review will discuss the health care and ICU cost, the evolving role of clinical pharmacists in managing critically ill patients, and their contributions in the ICU to mitigate the risks, improve patient outcomes, and decrease health care costs.

3.
Medicina (Kaunas) ; 57(2)2021 Jan 26.
Article in English | MEDLINE | ID: mdl-33530544

ABSTRACT

Traditionally, the management of patients with pulmonary embolism has been accomplished with anticoagulant treatment with parenteral heparins and oral vitamin K antagonists. Although the administration of heparins and oral vitamin K antagonists still plays a role in pulmonary embolism management, the use of these therapies are limited due to other options now available. This is due to their toxicity profile, clearance limitations, and many interactions with other medications and nutrients. The emergence of direct oral anticoagulation therapies has led to more options now being available to manage pulmonary embolism in inpatient and outpatient settings conveniently. These oral therapeutic options have opened up opportunities for safe and effective pulmonary embolism management, as more evidence and research is now available about reversal agents and monitoring parameters. The evolution of the pharmacological management of pulmonary embolism has provided us with better understanding regarding the selection of anticoagulants. There is also a better understanding and employment of anticoagulants in pulmonary embolism in special populations, such as patients with liver failure, renal failure, malignancy, and COVID-19.


Subject(s)
Anticoagulants/therapeutic use , Fibrinolytic Agents/therapeutic use , Pulmonary Embolism/drug therapy , Administration, Oral , Anticoagulants/administration & dosage , COVID-19/complications , Fibrinolytic Agents/administration & dosage , Humans , Liver Failure/complications , Neoplasms/complications , Renal Insufficiency/complications , Risk Factors , SARS-CoV-2
4.
Curr Cardiol Rev ; 13(2): 86-93, 2017.
Article in English | MEDLINE | ID: mdl-27586023

ABSTRACT

BACKGROUND: Endotoxin is a lipopolysaccharide (LPS) constituent of the outer membrane of most gram negative bacteria. Ubiquitous in the environment, it has been implicated as a cause or contributing factor in several disparate disorders from sepsis to heatstroke and Type II diabetes mellitus. Starting at birth, the innate immune system develops cellular defense mechanisms against environmental microbes that are in part modulated through a series of receptors known as toll-like receptors. Endotoxin, often referred to as LPS, binds to toll-like receptor 4 (TLR4)/ myeloid differentiation protein 2 (MD2) complexes on various tissues including cells of the innate immune system, smooth muscle and endothelial cells of blood vessels including coronary arteries, and adipose tissue. Entry of LPS into the systemic circulation ultimately leads to intracellular transcription of several inflammatory mediators. The subsequent inflammation has been implicated in the development and progression atherosclerosis and subsequent coronary artery disease and heart failure. OBJECTIVE: The potential roles of endotoxin and TLR4 are reviewed regarding their role in the pathogenesis of atherosclerotic heart disease. CONCLUSION: Atherosclerosis is initiated by inflammation in arterial endothelial and subendothelial cells, and inflammatory processes are implicated in its progression to clinical heart disease. Endotoxin and TLR4 play a central role in the inflammatory process, and represent potential targets for therapeutic intervention. Therapy with HMG-CoA inhibitors may reduce the expression of TLR4 on monocytes. Other therapeutic interventions targeting TLR4 expression or function may prove beneficial in atherosclerotic disease prevention and treatment.

5.
Am J Med Sci ; 346(3): 237-9, 2013 Sep.
Article in English | MEDLINE | ID: mdl-23974269

ABSTRACT

Endocarditis caused by Candida dubliniensis is a rare event and limited to few case reports. In this report, the authors present a patient with a history of intravenous drug use and hepatitis C and endocarditis involving a prosthetic aortic valve. Also reviewed are the treatment guidelines for Candida sp. endocarditis.


Subject(s)
Candida , Candidiasis/complications , Endocarditis/microbiology , Amphotericin B/therapeutic use , Antifungal Agents/therapeutic use , Candidiasis/drug therapy , Candidiasis/microbiology , Echinocandins/therapeutic use , Endocarditis/drug therapy , Fluconazole/therapeutic use , Humans , Lipopeptides/therapeutic use , Male , Micafungin , Middle Aged
6.
J Intensive Care Med ; 28(6): 334-40, 2013.
Article in English | MEDLINE | ID: mdl-22232203

ABSTRACT

Heatstroke is life-threatening condition characterized by hyperthermia and central nervous system disturbances. It can also be classified as a form of systemic inflammatory response syndrome with multiple organ dysfunction and in many ways resembles sepsis. Like sepsis, most patients with heatstroke demonstrate a hyperdynamic hemodynamic response. In contrast to sepsis, rhabdomyolysis may complicate management and initial fluid resuscitation is not well defined. We present an illustrative case report and review of literature.


Subject(s)
Critical Care/methods , Heat Stroke/physiopathology , Heat Stroke/therapy , Emergency Service, Hospital , Heat Stroke/diagnosis , Humans , Male , Vital Signs , Young Adult
7.
Infect Dis Ther ; 2(2): 175-85, 2013 Dec.
Article in English | MEDLINE | ID: mdl-25134480

ABSTRACT

Methicillin-resistant Staphylococcus aureus (MRSA) has become the dominant strain of Staphylococcus aureus in many communities of the United States. As a result, many clinicians are now empirically covering for this pathogen in the treatment of various skin and soft-tissue infections. Should this practice apply to cellulitis? In order to answer this question, we defined cellulitis and reviewed the pathogenesis, microbiology, and current studies of inpatient and outpatient antimicrobial therapy. The current evidence suggests empirical MRSA coverage for community-acquired cellulitis may not be necessary in non-purulent (non-suppurative) forms of this infection. Most cases are non-purulent and not amenable to culture although antibody studies indicate streptococci are the most common etiologic agents. Current studies of antimicrobial therapy tend to agree with this finding. Empirical beta-lactam therapy directed primarily at streptococci appears sufficient for non-purulent cellulitis regardless of the prevalence of MRSA in the community.

8.
Int J Infect Dis ; 15(3): e157-66, 2011 Mar.
Article in English | MEDLINE | ID: mdl-21177133

ABSTRACT

Vibrio vulnificus is a halophilic Gram-negative bacillus found worldwide in warm coastal waters. The pathogen has the ability to cause primary sepsis in certain high-risk populations, including patients with chronic liver disease, immunodeficiency, iron storage disorders, end-stage renal disease, and diabetes mellitus. Most reported cases of primary sepsis in the USA are associated with the ingestion of raw or undercooked oysters harvested from the Gulf Coast. The mortality rate for patients with severe sepsis is high, exceeding 50% in most reported series. Other clinical presentations include wound infection and gastroenteritis. Mild to moderate wound infection and gastroenteritis may occur in patients without obvious risk factors. Severe wound infection is often characterized by necrotizing skin and soft-tissue infection, including fasciitis and gangrene. V. vulnificus possesses several virulence factors, including the ability to evade destruction by stomach acid, capsular polysaccharide, lipopolysaccharide, cytotoxins, pili, and flagellum. The preferred antimicrobial therapy is doxycycline in combination with ceftazidime and surgery for necrotizing soft-tissue infection.


Subject(s)
Bacteremia/microbiology , Skin Diseases, Infectious/microbiology , Soft Tissue Infections/microbiology , Vibrio Infections/microbiology , Vibrio vulnificus/isolation & purification , Animals , Anti-Bacterial Agents/therapeutic use , Bacteremia/diagnosis , Bacteremia/drug therapy , Ceftazidime/therapeutic use , Doxycycline/therapeutic use , Drug Therapy, Combination , Humans , Male , Middle Aged , Risk Factors , Skin Diseases, Infectious/diagnosis , Skin Diseases, Infectious/drug therapy , Soft Tissue Infections/diagnosis , Soft Tissue Infections/drug therapy , Vibrio Infections/diagnosis , Vibrio Infections/drug therapy
9.
Am J Med Sci ; 340(6): 507-10, 2010 Dec.
Article in English | MEDLINE | ID: mdl-20861715

ABSTRACT

Mucormycosis is a rare life-threatening fungal infection occurring primarily in patients with diabetics or immunocompromised patients. The authors report a case of mucormycosis in a patient with diabetes complicated by bacterial brain abscess. The bacteria cultured from the abscess were Staphylococcus epidermidis and Enterococcus faecalis. The abscess was surgically drained and treated with antibiotics. A brief review of mucormycosis and brain abscess including treatment is provided in the discussion.


Subject(s)
Bacterial Infections/etiology , Brain Abscess/etiology , Brain Diseases/complications , Mucormycosis/complications , Nose Diseases/complications , Bacterial Infections/drug therapy , Brain Abscess/drug therapy , Enterococcus faecalis/isolation & purification , Humans , Male , Middle Aged , Staphylococcus epidermidis/isolation & purification
SELECTION OF CITATIONS
SEARCH DETAIL
...